Check for updates

OPINION ARTICLE

REVISED Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries? [version 2; peer review: 2 approved]

Sunil Shrestha ^{1,2}, Subish Palaian ³

¹Department of Pharmacy, Nepal Cancer Hospital and Research Center, Lalitpur, Nepal

²Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal

³Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates

v2 First published: 22 Jan 2020, 9:32
<https://doi.org/10.12688/f1000research.21962.1>

Latest published: 25 Feb 2021, 9:32
<https://doi.org/10.12688/f1000research.21962.2>

Abstract

Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. This paper highlights the serious breathing problems due to using gabapentin and pregabalin which was warned by the United States Food and Drug Administration on December, 2019. In this article, we tried to recommend suggestions for controlling these adverse drug reactions (ADRs). Safety reports of gabapentin and pregabalin should be obtained from concerned manufacturers and reviewed for respiratory depression effects. There should be strict prescription monitoring and drug use evaluation studies. Concurrent use of gabapentin and pregabalin with other respiratory depressants such as opioids should be strictly monitored. Educating patients can help in the early detection of ADRs due to gabapentin and pregabalin. Anecdotal reports on these medications should be encouraged.

Keywords

Gabapentin, Pregabalin, pharmacovigilance, Developing countries

Open Peer Review

Approval Status

	1	2
version 2 (revision) 25 Feb 2021		 view
version 1 22 Jan 2020	 view	 view

1. Sue E Jordan, Swansea University, Swansea, UK

2. Tetsu Ohnuma , Duke University Medical Center, Durham, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Sunil Shrestha (sunilcresta@gmail.com)

Author roles: **Shrestha S:** Conceptualization, Project Administration, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Palaian S:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Shrestha S and Palaian S. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Shrestha S and Palaian S. **Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?** [version 2; peer review: 2 approved] F1000Research 2021, 9:32 <https://doi.org/10.12688/f1000research.21962.2>

First published: 22 Jan 2020, 9:32 <https://doi.org/10.12688/f1000research.21962.1>

REVISED Amendments from Version 1

In response to the reviewer's comments and suggestions, we have made a few changes in the recommendations and conclusion sections of the article. Being widely used medications, it is recommended that vulnerable patients for developing respiratory side effects due to gabapentinoids should be identified in order to prevent exposure. The changes made in the revised version highlights two additional high risk population category for developing gabapentinoids induced respiratory depression such as patients with concurrent opioid use and patients administered with gabapentinoids on the day of surgery. The abstract was also amended in line with the recommendations section mentioning the risk of respiratory suppression when opioids are combined with gabapentinoids. Further, we cited literature confirming gabapentinoids induced respiratory suppression during the immediate post-operative period in a dose-dependent fashion among people who underwent total hip and knee arthroplasties. In the conclusion section, two new points have been added emphasizing the need to exercise more caution while gabapentinoids are used in patients concurrently with opioids, and the need for establishing effective safety monitoring and reporting systems to identify signals and its proper dissemination. The revised version of the article has three new references, 21–23, added to it.

Any further responses from the reviewers can be found at the end of the article

Introduction

Gabapentin and pregabalin, commonly known as gabapentinoids, have been widely used globally. Gabapentin is an anticonvulsant agent used in treating various illnesses such as amyotrophic lateral sclerosis, analgesia, anxiety, neuralgia, restless legs syndrome and bipolar disorder¹. Pregabalin is commonly used to treat painful diabetic neuropathy, fibromyalgia, diabetic neuropathy, cancer chemotherapy-induced neuropathic pain, post-herpetic neuralgia, trigeminal neuralgia, and post-operative pain^{2,3}. Pregabalin also acts to be an effective treatment therapy in refractory partial-onset seizures and the existing data recommends that pregabalin may be favorable as adjunctive therapy in adults with generalized or social anxiety disorder³.

As per the available safety data, the use of gabapentin and pregabalin may cause neuropsychiatric related adverse drug reactions (ADRs) followed by hepatic, cutaneous and hematological reactions⁴. Suicidal ideation, cognitive impairment, motor incoordination, dizziness are also severe forms of ADRs associated with gabapentinoids⁵. The use of pregabalin is associated with hematological ADRs, and gabapentin is also associated with liver toxicity.

Respiratory concerns with gabapentin and pregabalin

Respiratory depression, a highly mortal condition, due to gabapentin and pregabalin has been emerging for the past few years even in patients who were not on opioids, though post-marketing studies showed similar effects among patients taking these medications concurrently along with other respiratory suppressants⁶. In December 2019, the United States Food and Drug Administration (US FDA) issued a drug safety alert on serious breathing problems with gabapentin and

pregabalin noticed when used along with central nervous system (CNS) depressants or in patients with lung problems. US FDA reviewed data from the FDA Adverse Event Reporting System (FAERS)⁷ database of almost five years, i.e. from January 1, 2012 – October 26, 2017, which revealed 49 cases gabapentinoid-induced respiratory depression. Out of 49, most cases (n=34; 69.3%) were reported with pregabalin and 30.6% (n=15) cases were reported with gabapentin. Of these cases, 92% reported either a respiratory risk factor, including age-related loss of lung function, or the use of a CNS depressant. This report also revealed that 24% percent (n=12) of the 49 patients with respiratory depression died due to respiratory depression and were taking gabapentinoids.

What do the recent respiratory problems of gabapentin and pregabalin mean for pharmacovigilance in the developing world?

Since these ADR reports are from developed countries, it is difficult for regulators in developing countries to take decisions on these two medications that are also abundantly used in the developing world. For example, in India, there are escalating sales of gabapentin and pregabalin and while comparing the sales in 2017 to those in 2019, it was found that sales of gabapentin and pregabalin increased by 25% and 16%, respectively⁸.

As is well documented in the literature^{9–11}, pharmacovigilance programs in developing countries lack robust reporting of ADRs and underreporting is a common issue. To bring any regulatory changes such as labeling changes or even ultimately banning the medications, one needs evidence, which largely is lacking at this point among developing countries¹².

There have often been issues like this in the past where safety concerns emerge, mainly from the developed world, with drugs like selective cyclooxygenase-2 inhibitors (coxibs)¹³, cerivastatin¹⁴ and glitazones¹⁵, and the developing world, due to lack of stringent pharmacovigilance mechanisms, is left with little or no choice but to follow the actions taken by the developed world. In addition, developing countries lack options for communicating pharmacovigilance information¹⁶ among key stakeholders, including consumers, which is another concern. It is astonishing that many developing countries where large quantities of medicines are used still lack strong mechanisms to monitor the safety of their products.

Recommendations

In the current scenario, safety reports of gabapentinoids should be obtained from concerned manufacturers and reviewed for respiratory depression effects. As understood, manufacturers are an important partner in the pharmacovigilance process with the unique advantage of formulation related information. The periodic safety update reviews (PSURs) submitted by the manufacturers of gabapentinoids can be an important source for new signal detection¹⁷. In addition, the pharmaceutical manufacturer also has an obligation to report serious ADRs to the regulatory authorities¹⁸.

Healthcare professionals should be watchful and report ADRs associated with gabapentinoids. Spontaneous reporting of

suspected ADRs in the past have been crucial in detecting ADRs at an early stage¹⁹.

Labeling changes should be made, and a drug can be banned if needed²⁰. New warnings are necessary to incorporate into prescribing information, including package inserts about possible respiratory depression⁸. Concurrent use of these drugs with other respiratory depressants should be strictly monitored. Anecdotal reports on these medications should be encouraged as they can be crucial in detecting ADRs²¹. If noticed, causality and severity assessments should be made for the suspected ADRs.

While these medications are used widely, it is also crucial to identify the vulnerable population at a high risk of developing respiratory side effects. It is evident that concurrent opioid use increases the risk for respiratory depression²². Further, a retrospective study involving 175,787 patients who underwent colorectal surgery reported administration of gabapentinoids on the day of surgery was associated with an increased risk of pulmonary complications²³. In another retrospective analysis involving 858,306 patients who underwent total hip and knee arthroplasties, gabapentinoids showed respiratory suppression during the immediate post-operative period in a dose-dependent fashion²⁴. The patients on these two medications (and the ones closely chemically related to them) should be provided with proper counseling. Educating patients can help in the early

detection of ADRs and active participation of patients can help identify adverse events and ADRs, describe ADRs, and ultimately prevent drug-related harm²⁵. Hospital drug and therapeutics committees play a crucial role in situations like this by disseminating information within the hospital²⁶. Social media may also play a crucial role in the signal generation of suspected ADRs in these situations²⁷. Hospitals using these medications should develop risk management plans associated with gabapentinoids usage and must disseminate any safety issues to concerned authorities.

Conclusions

Drug safety is a constantly evolving process and one must be vigilant on the use of these medications. It is suggested to exercise more caution while these drugs are used in patients and concurrent opioid administration. It is also essential to establish effective safety monitoring and reporting systems to identify signals and its proper dissemination. Healthcare professionals, especially prescribing physicians, nurses and pharmacists should be more cautious about using these medications in vulnerable people. Patient education and prescription restrictions of gabapentin and pregabalin may be needed until more data are available.

Data availability

No data is associated with this article.

References

- Quintero GC: **Review about gabapentin misuse, interactions, contraindications and side effects.** *J Exp Pharmacol.* 2017; **9**: 13–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Inoue K, Takano H: **Gabapentin for refractory chronic cough.** *Lancet.* 2013; **381**(9867): 623.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tassone DM, Boyce E, Guyer J, et al.: **Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.** *Clin Ther.* 2007; **29**(1): 26–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fuzier R, Serres I, Guillon E, et al.: **Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.** *Drug Saf.* 2013; **36**(1): 55–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Toth C: **Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.** *Ther Adv Drug Saf.* 2014; **5**(1): 38–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gabapentin and the risk of respiratory depression without concomitant opioids. 2017.
[Reference Source](#)
- FDA: **Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS).** 2019.
[Reference Source](#)
- ThePrint: **US flags two top neurological drugs used in India, warns of serious breathing difficulties.** 2019.
[Reference Source](#)
- Elshafie S, Zaghoul I, Roberti AM: **Pharmacovigilance in developing countries (part I): importance and challenges.** *Int J Clin Pharm.* 2018; **40**(4): 758–763.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Biswas P: **Pharmacovigilance in Asia.** *J Pharmacol Pharmacother.* 2013; **4**(Suppl 1): S7–S19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Amin MN, Khan TM, Dewan SM, et al.: **Cross-sectional study exploring barriers to adverse drug reactions reporting in community pharmacy settings in Dhaka, Bangladesh.** *BMJ Open.* 2016; **6**(8): e010912.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sekine S, Pinnow EE, Wu E, et al.: **Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.** *Clin Pharmacol Ther.* 2016; **100**(1): 102–108.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mukherjee D: **Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.** *Biochem Pharmacol.* 2002; **63**(5): 817–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Saito M, Hirata-Koizumi M, Miyake S, et al.: **Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States.** *Kokuritsu Iyakuin Shokuhin Eisei Kenkyusho Hokoku.* 2005; **(123)**: 41–5.
[PubMed Abstract](#)
- Ensuring drug safety: lessons from the thiazolidinediones. *Lancet.* 2007; **370**(9593): 1101.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Abiri OT, Johnson WCN: **Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone.** *J Pharm Policy Pract.* 2019; **12**: 13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mammi M, Citraro R, Torcasio G, et al.: **Pharmacovigilance in pharmaceutical companies: An overview.** *J Pharmacol Pharmacother.* 2013; **4**(Suppl 1): S33–S37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nukala S: **Pharmacovigilance: the role of pharmaceutical companies to protect patients from adverse drug reactions.** 2017.
[Reference Source](#)
- Wysowski DK, Swartz L: **Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.** *Arch Intern Med.* 2005; **165**(12): 1363–1369.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hoffman KB, Dimbil M, Tatonetti NP, et al.: **A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event**

reports. *Drug Saf.* 2016; **39**(6): 561–575.

[PubMed Abstract](#) | [Publisher Full Text](#)

21. Onakpoya IJ, Heneghan CJ, Aronson JK: **Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.** *BMC Med.* 2016; **14**: 10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Johansen ME: **Gabapentinoid Use in the United States 2002 Through 2015.** *JAMA Intern Med.* 2018; **178**(2): 292–294.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ohnuma T, Krishnamoorthy V, Ellis AR, *et al.*: **Association 'Between Gabapentinoids on the Day of Colorectal Surgery and Adverse Postoperative Respiratory Outcomes.** *Ann Surg.* 2019; **270**(6): e65–e67.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Ohnuma T, Raghunathan K, Moore S, *et al.*: **Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties.** *J Bone Joint Surg Am.* 2020; **102**(3): 221–229.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Berrewaerts J, Delbecq L, Orban P, *et al.*: **Patient Participation and the Use of Ehealth Tools for Pharmacovigilance.** *Front Pharmacol.* 2016; **7**: 90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Tyler LS, Cole SW, May JR, *et al.*: **ASHP guidelines on the pharmacy and therapeutics committee and the formulary system.** *Am J Health Syst Pharm.* 2008; **65**(13): 1272–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Pappa D, Stergioulas LK: **Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions.** *Int J Data Sci Anal.* 2019; **8**(2): 113–135.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 26 February 2021

<https://doi.org/10.5256/f1000research.54542.r80176>

© 2021 Ohnuma T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tetsu Ohnuma

Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA

Thank you for addressing my points. I don't have further comments to make.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Perioperative multimodal analgesics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 17 August 2020

<https://doi.org/10.5256/f1000research.24217.r68652>

© 2020 Ohnuma T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tetsu Ohnuma

Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA

This is an interesting article on a relevant topic. It is well written and important points are clearly presented.

Gabapentinoids, gabapentin and pregabalin, are being increasingly dispensed for indications outside US FDA labelling, particularly as part of multimodal analgesia in the perioperative setting.

Emerging evidence from pre-clinical, human volunteer, inpatient, and outpatient studies suggests that their use in combination with opioids may increase the risk of respiratory depression.

In our recent studies, use of gabapentinoids on the day of surgery was associated with increased risk of postoperative pulmonary complications in patients who underwent colorectal surgery¹. We also found that in-hospital use of both gabapentin and pregabalin had dose dependent associations with pulmonary complications in the immediate postoperative period after total hip and knee arthroplasties².

The adverse effect of perioperative use of gabapentinoids can occur in all countries. While differences in risk across different populations are unclear (for example, the prevalence of pulmonary complications after concurrent use of opioids with gabapentinoids may differ among races), we suggest that a caution be warranted when these drugs are used in combination with opioids. Obviously, it is essential to establish effective safety reporting systems to detect signals of adverse events and disseminate the information to all relevant sections.

References

1. Ohnuma T, Krishnamoorthy V, Ellis AR, Yan R, et al.: Association 'Between Gabapentinoids on the Day of Colorectal Surgery and Adverse Postoperative Respiratory Outcomes.*Ann Surg.* **270** (6): e65-e67 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Ohnuma T, Raghunathan K, Moore S, Setoguchi S, et al.: Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties.*J Bone Joint Surg Am.* 2020; **102** (3): 221-229 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Partly

Are arguments sufficiently supported by evidence from the published literature?

Partly

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Perioperative multimodal analgesics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 31 July 2020

<https://doi.org/10.5256/f1000research.24217.r67201>

© 2020 Jordan S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sue E Jordan

College of Human and Health Sciences, Swansea University, Swansea, UK

Thank you for the opportunity to review this interesting short opinion paper.

The SmPCs for gabapentin and pregabalin include respiratory problems under 'undesirable effects'; however, as the authors say, there are no recommendations to apply this to practice. This applies in all countries, particularly post-industrial societies. Our trial and observation study found too many unaddressed respiratory problems ^{1,2}.

Whilst I concur with the sentiments expressed, I feel these should be placed in the context of full patient monitoring for the full range of possible adverse effects of prescribed medicines. Respiratory depression is extremely important, as indicated, but it is also important to check patients for other possible undesirable effects of medicines and unmedicated problems, including pain, sedation and falls. We have shown the effectiveness of this approach, and would like to see it more widely adopted ^{1,2}. Our website gives free access to our strategy.
<http://www.swansea.ac.uk/adre/>.

References

1. Jordan S, Gabe-Walters ME, Watkins A, Humphreys I, et al.: Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial. *PLoS One*. 2015; **10** (10): e0140203 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Jordan S, Banner T, Gabe-Walters M, Mikhail JM, et al.: Nurse-led medicines' monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study. *PLoS One*. 2019; **14** (9): e0220885 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research